Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Reuters

07-08

Dermata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled "Compositions for the treatment of skin conditions," is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2549544620"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549544620\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2549544620?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549544620","market":"nz","top_or_hot":-1,"title":"Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLb3zG3H:1","article_id":"2549544620","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549544620","pubTimestamp":1751976052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the ori","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","DRMA":"Dermata Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Dermata Therapeutics宣布授予创新多汗症治疗澳大利亚专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9},"content_text":"Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    \n\nDermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}